As previously mentioned, MCP-1 participates in progressive renal fibrosis by binding to its receptor, CCR2.[2] This indicates that MCP-1/CCR2 axis seems to be a promising target for treating DN. This evidence concerns the gene CCL2 and liver dysplastic nodule.